<?xml version="1.0" encoding="UTF-8"?>
<p>After large-scale epidemics, CP gets increasing attention as a preferred therapeutic tool for many reasons: collecting a large volume per session, frequent donations are possible, and without any impact on the donorâ€™s hemoglobin [
 <xref rid="ref014" ref-type="bibr">14</xref>], which seems an attractive method in case of COVID-19. Currently, there are around 1,159,953 patients who have survived and the number keeps increasing, and we believe that many of them would donate their plasma to end this pandemic. However, in order to have an effective CP infusion, donor plasma should be tested for antibody activity and neutralization activity. In a resource limited situation, ELISA IgG could be a substitute for neutralization tests [
 <xref rid="ref011" ref-type="bibr">11</xref>].
</p>
